Cencora, Inc. (COR) stock
CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 14/3022% above fair value
$349.88+1.17 (+0.34%)
Close on Nov 11, 2026Market cap $66.77BP/E 26.0Yield 0.63%
Cencora EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Cencora's EPS for the twelve months ending Jun 30, 2026 was $13.47, up 38.6% year over year. For fiscal 2025 it was $7.96, up 5.7% from the year before. The highest annual figure on record is $8.53 in fiscal 2023.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $7.96 | +5.7% |
| FY2024 | Sep 30, 2024 | $7.53 | -11.7% |
| FY2023 | Sep 30, 2023 | $8.53 | +6.1% |
| FY2022 | Sep 30, 2022 | $8.04 | +8.8% |
| FY2021 | Sep 30, 2021 | $7.39 | – |
| FY2020 | Sep 30, 2020 | -$16.65 | -512.1% |
| FY2019 | Sep 30, 2019 | $4.04 | -46.3% |
| FY2018 | Sep 30, 2018 | $7.53 | +359.1% |
| FY2017 | Sep 30, 2017 | $1.64 | -74.1% |
| FY2016 | Sep 30, 2016 | $6.32 | – |
| FY2015 | Sep 30, 2015 | -$0.63 | -154.3% |
| FY2014 | Sep 30, 2014 | $1.16 | -37.0% |
| FY2013 | Sep 30, 2013 | $1.84 | -34.3% |
| FY2012 | Sep 30, 2012 | $2.80 | +10.2% |
| FY2011 | Sep 30, 2011 | $2.54 | +14.4% |
| FY2010 | Sep 30, 2010 | $2.22 | +33.7% |
| FY2009 | Sep 30, 2009 | $1.66 | +115.6% |
| FY2008 | Sep 30, 2008 | $0.77 | -38.4% |
| FY2007 | Sep 30, 2007 | $1.25 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $3.94 | +11.9% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $8.40 | +128.3% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $2.87 | +14.8% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$1.74 | -8800.0% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $3.52 | +45.5% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $3.68 | +76.1% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $2.50 | -16.1% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $0.02 | -98.8% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $2.42 | +3.0% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $2.09 | -1.9% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $2.98 | +27.9% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $1.72 | +22.9% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $2.35 | +22.4% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $2.13 | -17.8% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $2.33 | +9.4% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $1.40 | -32.7% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $1.92 | +37.1% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $2.59 | +23.3% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $2.13 | +17.7% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $2.08 | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $1.40 | -0.7% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $2.10 | -54.7% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $1.81 | +101.1% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$23.74 | -3868.3% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $1.41 | -1.4% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $4.64 | +3469.2% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $0.90 | -51.1% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $0.63 | -41.1% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $1.43 | +14.4% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $0.13 | -89.9% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $1.84 | -52.8% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $1.07 | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $1.25 | +443.5% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $1.29 | -30.6% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $3.90 | +251.4% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$1.58 | -346.9% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $0.23 | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $1.86 | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $1.11 | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $0.64 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?